Viewing nowValsartan 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Unimed Pharma Co., Ltd.

MFDS item code 201602930 · Approved 2016.05.25 · Insurance code 649507220
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This medication is effective in controlling essential hypertension. It is also used for patients with heart failure who are intolerant to ACE inhibitors, particularly for classes II to IV heart failure according to NYHA classification. Moreover, it helps to reduce the risk of mortality in stable patients with left ventricular failure or dysfunction following a myocardial infarction. In summary, it is used for controlling essential hypertension, treating heart failure, and reducing the risk of mortality after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medication once daily; do not exceed 80 mg once daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medication with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher; however, as there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug may cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. It should not be used in some patients, including pregnant women or those who may become pregnant, nursing mothers, patients with severe liver impairment, severe renal impairment, and hereditary angioedema. Caution is advised for elderly patients, those with hyperkalemia, liver impairment, heart failure, or myocardial infarction, as these conditions may require careful monitoring of blood pressure, starting with a low dose and observing the condition closely. This drug lowers blood pressure, which may cause symptoms such as hypotension, dizziness, or fainting upon initial use. In such cases, medical attention should be sought immediately. Caution is also warranted when taken together with potassium-sparing diuretics or potassium supplements, as this may dangerously elevate blood potassium levels. Consult healthcare professionals before taking this drug with other antihypertensives or non-steroidal anti-inflammatory drugs (NSAIDs), as it may affect efficacy or kidney function. Regular monitoring of renal function, blood potassium levels, and blood pressure during treatment is crucial. This drug is not recommended for use in children and adolescents, as safety and efficacy have not been established. In case of overdose, severe hypotension, altered consciousness, or shock may occur, requiring immediate emergency treatment. Lastly, this drug should be kept out of reach of children, and it is preferable not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a tightly sealed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Light yellow-brown rectangular film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Unimed Pharma Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.